Bladder Cancer, Fluorescence <i>in situ</i> Hybridization (FISH)
| Bladder Cancer, Fluorescence in situ Hybridization (FISH) | | | |
| Number | | 496414 |
| CPT | | 88271 (x4); 88274; 88291 |
| Related Information | | Oncology-Based FISH |
| Synonyms | | FISH, Bladder Cancer ; Urothelial Carcinoma, FISH ; UroVysion, FISH |
Specimen | | Urine, fixed, refrigerated |
| Volume | | 60 mL urine mixed with preservative in TCC Monitor kit |
| Minimum Volume | | 33 mL urine mixed with preservative in TCC Monitor kit |
| Container | | TCC Monitor kit (People Soft Item ID: 44921). Other
containers that are accepted, but not recommended:
PreservCyt® vial, Cytology Special Studies Kit (People
Soft Item ID: 3203), or sterile urine container with
Carbowax® fixative (2 part urine: 1 part fixative). |
| Collection | | Step 1: Use the large, open cup in the kit to collect the
urine specimen. First void of the day is preferred. Ensure
that the urine specimen reaches the minimum fill line of 33
mL.
Step 2: Slowly pour urine into the smaller container to the
maximum fill line of 90 mL.
Step 3: Tighten the lid until you hear a click in order to
prevent leakage. |
| Storage Instructions | | Specimen should be refrigerated at 2°C to 8°C and shipped
on cool packs. Do not Freeze. |
| Causes for Rejection | | Incorrect fixative; significant contamination with blood
obscuring bacterial over-growth; inadequate specimen
cellularity |
| Use | | The assay is designed to detect aneuploidy for chromosomes
3, 7, 17, and loss of the 9p21 locus via fluorescence in
situ hybridization (FISH) in urine specimens from
subjects with transitional cell carcinoma of the bladder.
This assay does not detect other chromosomal or genetic
alterations. Results are intended for use as a noninvasive
method of monitoring for tumor recurrence in conjunction
with cystoscopy in patients previously diagnosed with
bladder cancer. The clinical interpretation of test results
should be evaluated within the context of the patient's
medical history and other diagnostic laboratory test
results. |
| Limitations | | Positive FISH results in the absence of other signs or
symptoms of bladder cancer recurrence may be evidence of
other urinary tract related cancers (eg, ureter, urethra,
renal, and/or prostate in males), and further patient
follow-up may be helpful. Negative FISH results in the
presence of other signs and symptoms of bladder cancer
recurrence may need to be regarded as suspicious
false-negative results; repeat testing may be indicated.
Although the assay was designed to detect chromosome
changes associated with most bladder cancers, there will be
some bladder cancers whose genetic changes are not targeted
by this test. |
| Methodology | | Fluorescence in situ hybridization (FISH); urine cytology |
| References | | Halling KC, King W, Sokolova
IA. et al. "A Comparison of Cytology and Fluorescence in
situ Hybridization for the Detection of Urothelial
Carcinoma," J Urol, 2000; 164(5):1768-1775.
Sokolova IA, Halling KC, Jenkins
RB. et al. "The Development of a Multitarget, Multicolor
Fluorescence in situ Hybridization Assay for the Detection
of Urothelial Carcinoma in Urine," J Molec Diag,
2000; 2(3):116-123. |
|